In March 2007, the FDA approved lapatinib in combination with capecitabine for HER-2-positive breast cancer previously treated with anthracyclines, paclitaxel, and trastuzumab [73] In February 2010, the FDA approved lapatinib in combination with letrozole for the first-line treatment of hormone receptor (HR)-positive and HER-2 overexpressing postmenopausal metastatic breast cancer [74]. Here, ERBB2 is linked to breast cancer.